236 related articles for article (PubMed ID: 34941996)
21. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
22. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
[TBL] [Abstract][Full Text] [Related]
23. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
25. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.
Dufner V; Sayehli CM; Chatterjee M; Hummel HD; Gelbrich G; Bargou RC; Goebeler ME
Blood Adv; 2019 Aug; 3(16):2491-2498. PubMed ID: 31451445
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
28. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
29. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M; Colombetti S; Herter S; Sam J; Perro M; Chen S; Bianchi R; Richard M; Schoenle A; Nicolini V; Diggelmann S; Limani F; Schlenker R; Hüsser T; Richter W; Bray-French K; Hinton H; Giusti AM; Freimoser-Grundschober A; Lariviere L; Neumann C; Klein C; Umaña P
Clin Cancer Res; 2018 Oct; 24(19):4785-4797. PubMed ID: 29716920
[No Abstract] [Full Text] [Related]
30. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
31. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
32. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.
Hijazi Y; Klinger M; Kratzer A; Wu B; Baeuerle PA; Kufer P; Wolf A; Nagorsen D; Zhu M
Curr Clin Pharmacol; 2018; 13(1):55-64. PubMed ID: 29773068
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
35. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
[TBL] [Abstract][Full Text] [Related]
36. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
37. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
Messori A; Rivano M; Mengato D; Chiumente M
Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
[TBL] [Abstract][Full Text] [Related]
38. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
39. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
Song YQ; Zhang HL; Huang HQ; Zhang QY; Jing HM; Wang C; Wu C; Li DH; Dai Y; Humphrey K; Zhu J
Haematologica; 2024 Apr; 109(4):1269-1273. PubMed ID: 37855035
[No Abstract] [Full Text] [Related]
40. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]